Linear Sugar-Cluster Insulin Conjugates for Glucose-Responsive Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing controlled-release drug delivery systems fail to provide drugs in proportion to the body's glucose concentration, leading to inadequate insulin therapy for diabetes and a risk of hypoglycemia.
Innovation Solution
Development of glucose-responsive insulin conjugates with linear glycosylated amino acid oligomers covalently attached to insulin, allowing for a pharmacokinetic and pharmacodynamic profile responsive to glucose or alpha-methylmannose concentrations, balancing binding with insulin and mannose receptors.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If insulin is provided in a slow release format independent of external or internal factors, then the drug delivery system is simple to manufacture and administer, but the insulin release is not responsive to varying glucose concentration leading to inadequate glycemic control and hypoglycemia risk
Solution Approach 1:
The patent applies dynamics by creating an insulin conjugate system that dynamically adjusts its pharmacokinetic and pharmacodynamic properties in response to changing glucose concentrations. The linear oligomer sugar cluster moiety enables the insulin to transition between different binding states (insulin receptor vs. mannose receptor) based on glucose levels, making the drug delivery system adaptive rather than static.
Solution Approach 2:
The patent utilizes parameter changes by modifying the insulin molecule through conjugation with linear oligomer sugar clusters, which alters the insulin's pharmacokinetic and pharmacodynamic parameters. This chemical modification enables the insulin to respond to glucose concentration changes by changing its binding affinity and clearance rate, thereby adjusting its therapeutic effect according to physiological needs.
2Reliability
If a cluster of sugar moieties is conjugated to insulin to enable glucose responsive pharmacokinetic properties, then the insulin becomes responsive to endogenous glucose concentration, but the device complexity increases due to the conjugation process and structure
Solution Approach 1:
The patent applies composite materials by combining insulin with linear oligomer sugar clusters to create a hybrid conjugate molecule. This composite structure integrates the glucose-responsive properties of sugar moieties (recognized by mannose receptors) with the glucose-lowering activity of insulin, achieving responsive drug delivery through material composition rather than complex mechanical systems.
Solution Approach 2:
The patent uses segmentation by dividing the conjugate into distinct functional modules: the insulin portion responsible for glucose lowering and the linear oligomer sugar cluster portion responsible for glucose-sensing and mannose receptor binding. This modular segmentation allows each component to perform its specific function while simplifying the overall design compared to integrated complex systems.
3Reliability
If insulin replacement therapy is administered to diabetic patients, then the basic insulin need is met, but the therapy is insufficient due to the inability of exogenous insulins to function in response to varying glucose concentration
Solution Approach 1:
The patent implements self-service by designing an insulin conjugate that automatically responds to glucose concentration changes without requiring external control systems. The conjugate's pharmacokinetic and pharmacodynamic properties are inherently responsive to glucose levels through the linear oligomer sugar cluster's interaction with mannose receptors, enabling the drug to self-regulate its effectiveness based on physiological conditions.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The conjugates effectively lower glucose levels in response to alpha-methyl mannose, offering a safer treatment for diabetes with reduced hypoglycemia risk.
Implementation Method 1
the conjugates comprise an insulin or insulin analog molecule covalently attached at its N-terminal amino groups of A-chain, such as A1Gly, and B-chain B1Phe, respectively, or 8-amino group of the side chain of B29Lys
Implementation Method 2
The cluster of sugar moieties, acting as substrate of endogenous mannose receptor, potentially affect the pharmacokinetic properties of their corresponding insulin conjugates in a way that is sensitive to the endogenous glucose concentration
Data Source
AI summary
Glucose-responsive insulin conjugates that contain one or more linear oligomer sugar cluster are provided. Such insulin conjugates that may display a pharmacokinetic (PK) and/or pharmacodynamic (PD) profile that is responsive to the systemic concentrations of a saccharide such as glucose or alpha-methylmannose, even when administered to a subject in need thereof in the absence of an exogenous multivalent saccharide-binding molecule.